HaiYanMD

Associate Professor, Pathology, Duke Univ Sch of Med

Dr. Yan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

6 citations
Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells
Kefeng Lei, Ran Sun, Lee H. Chen, Bill H. Diplas, Casey J. Moure
Scientific Reports. 2018-08-21
172 citations
The implications of IDH mutations for cancer development and therapy
Christopher J. Pirozzi, Hai Yan
Nature Reviews. Clinical Oncology. 2021-06-15
114 citations
Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy
Chunfeng Qu, Yuting Wang, Pei Wang, Kun Chen, Minjie Wang
Proceedings of the National Academy of Sciences of the United States of America. 2019-03-26

Journal Articles

The Genomic Landscape of TERT Promoter Wildtype-IDH Wildtype Glioblastoma
Daniel B. Loriaux, Darel D. Bigner, Fausto J. Rodriguez, Hai Yan, Bil H. Diplas, Henry S. Friedman, Roger E. McLendon, Nature

REMD Biotherapeutics Announces Positive Top-Line Results in a Phase 2 Program of Lead Product Candidate Volagidemab in Patients with Type 1 DiabetesJune 28th, 2021
REMD Biotherapeutics Completes Enrollment and Announces Top-Line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 DiabetesJanuary 7th, 2021
Lessons in History, Hope and Living with Lynch Syndrome from the “Daughter of Family G”August 26th, 2020
Join now to see all